American Association for Cancer Research

sorry, we can't preview this file

23266066cir210147-sup-261189_2_supp_7208363_qx2njy.docx (37.24 MB)

Supplementary Data from Context-Dependent Immunomodulatory Effects of MEK Inhibition Are Enhanced with T-cell Agonist Therapy

Download (37.24 MB)
journal contribution
posted on 2023-04-04, 01:05 authored by Lauren Dennison, Amanda Ruggieri, Aditya Mohan, James Leatherman, Kayla Cruz, Skylar Woolman, Nilofer Azad, Gregory B. Lesinski, Elizabeth M. Jaffee, Mark Yarchoan

Supplementary Figures 1-5 and Supplementary Table 1


Pediatrics/Winship Flow Cytometry Core of Winship Cancer Institute of Emory University, Children's Healthcare of Atlanta



Johns Hopkins Bloomberg‐Kimmel Institute for Cancer Immunotherapy

Winship Cancer Institute

Pediatric/Winship Flow Cytometry Core

National Cancer Institute Specialized Program of Research Excellence (SPORE) in Gastrointestinal Cancers

NIH Center Core Grant

Experimental Therapeutics Clinical Trials Network

Passano Foundation

F. Hoffmann-La Roche, Ltd



MEK inhibition (MEKi) is proposed to enhance antitumor immunity but has demonstrated mixed results as an immunomodulatory strategy in human clinical trials. MEKi exerts direct immunomodulatory effects on tumor cells and tumor-infiltrating lymphocytes (TIL), but these effects have not been independently investigated. Here we modeled tumor-specific MEKi through CRISPR/Cas-mediated genome editing of tumor cells [MEK1 knockout (KO)] and pharmacologic MEKi with cobimetinib in a RAS-driven model of colorectal cancer. This approach allowed us to distinguish tumor-mediated and tumor-independent mechanisms of MEKi immunomodulation. MEK1 KO tumors demonstrated upregulation of JAK/STAT signaling, enhanced MHCI expression, CD8+ T-cell infiltration and T-cell activation, and impaired tumor growth that is immune dependent. Pharmacologic MEKi recapitulated tumor-intrinsic effects but simultaneously impaired T-cell activation in the tumor microenvironment. We confirmed a reduction in human peripheral-lymphocyte activation from a clinical trial of anti–PD-L1 (atezolizumab) with or without cobimetinib in biliary tract cancers. Impaired activation of TILs treated with pharmacologic MEKi was reversible and was rescued with the addition of a 4-1BB agonist. Collectively, these data underscore the ability of MEKi to induce context-dependent immunomodulatory effects and suggest that T cell–agonist therapy maximizes the beneficial effects of MEKi on the antitumor immune response.